摘要
目的：观察不同剂量的阿托伐他汀对急性冠脉综合征（ACS）患者PCI围手术期的炎症因子及血清黏附因子影响。方法：将人选的120例ACS患者随机分为治疗组和对照组，每组60例，治疗组给予阿托伐他汀40mg／d，对照组给予阿托伐他汀20mg／d，自术前至术后1个月。于PCI术前及术后1周、2周测血浆hs-CRP，及血浆可溶性细胞间黏附分子（soluble intercellular adhesionmolecuh - 1 , sICAM - 1）、血管细胞黏附分子（ soluble vascular cell adhesion molecule - 1, sV-CAM-1）。结果：两组术后1周hs-CRP均明显升高（P〈0．01），但对照组较治疗组明显升高（P〈0．01），经治疗后2周两组hs-CRP较术前均降低（P〈0．01），治疗组降低更为显著（P〈0．01）。治疗组在PCI术后第7d，两种血清黏附分子水平显著低于对照组（P〈0．01）。结论：较大剂量阿托伐他汀能够抑制PIC术后炎症反应，显著降低sICAM-1、sV-CAM-1水平，进而减少PCI术后不良事件的发生。
OBJECTIVE ： To explore the influence of different doses of atorvastatin on adhesion molecule and inflammatory cytokines levels in patients with acute coronary syndrome （ACS） after receiving percutaneous coronary interveutiou （PCI）. METHODS： 120 ACS patients were randomly divided into treatment group （n = 60） and control group （n = 60）. The treatment group received atorvastatin （40mg/d） and the control group received atorvastatin （20mg/d） from the preoperative to postoperative mouths. Plasma hs - CRP, plasma soluble intercellular adhesion molecule （ sICAM - 1 ） and vascular cell adhesion molecule （ sVCAM - 1 ） were measured before PCI and subsequently after PCI for one week and two weeks. RESULTS： hs - CRP were significantly higher （P 〈 0. 01 ） in the first week after PCI, but the treatment group was significantly higher than those in the control group （P 〈 0. 01 ）. hs - CRP lelves were all decreased in two groups in two weeks after treatment （P 〈 0. 01 ） and the treatment group were significantly lower （ P 〈 0. 01 ）. In treatment group in the first seven days after PCI two kinds of adhesion molecules in the serum levels were significantly lower than those in control group （P 〈 0. 01 ）. CONCLUSION ： Larger dose of atorvastatin can inhibit inflammation after PCI and significantly reduce sICAM - 1 and sVCAM - 1 levels and reduce the occurrence of adverse events after PCI.
出处
《国际老年医学杂志》
2013年第6期246-250,共5页
International Journal of Geriatrics
